Clinical Research Study Overview

The DZNE does not only conduct locally designed studies at the individual sites. Due to its structure, it is possible that subjects in multicenter studies can be examined at all participating DZNE sites.

Researchers at the DZNE and at the cooperating institutions are looking for volunteer study participants:

  • At nine German sites, the DZNE is conducting studies in at-risk individuals and those affected by a neurodegenerative disease (e.g., Alzheimer's, dementia, or Parkinson's disease).
  • In addition, we are also looking for healthy study subjects and relatives of persons with neurodegenerative diseases.
  • Depending on the study, an expense allowance will be paid.

If you would like to support our research by participating, here you will find an overview of all clinical studies for which the DZNE is currently looking for participants.

You can refine your search using the filters for the target group, a specific diagnosis and a certain DZNE site.

7T-TGA (high-resolution MRI imaging in TGA patients: a retrospective and prospective study)
High-resolution MRI imaging as evidence of a structural cause in transient global amnesia (TGA), in which there is disruption of anterograde and also retrograde memory such that newly learned or experienced material is not retained.
The aim of this study is to investigate the influence of rituximab (Rixathon®) on the progression of disease in patients with amyotrophic lateral sclerosis (ALS) compared to a placebo. The study is funded by the German Federal Ministry of Education and Research (BMBF).
Aphantasia (Neural correlates of aphantasia: assessments using functional magnetic resonance imaging)
To investigate the causes and consequences of aphantasia, aphantasists as well as unaffected control subjects are sought.
ApoE Navi (Influences of the APOE-ε4 genotype and other Alzheimer´s disease (AD) related genes on spatial navigation ability and its neural basis)
The relationship between spatial orientation ability and the context dependence of spatial representations in entorhinal cortex and hippocampus in APOE-ε4 allele carriers is investigated.
ARCA (Autosomal-Recessive Cerebellar Ataxias)
In this DZNE network research project (Autosomal Recessive Cerebellar Ataxia Registry, ARCA registry), modern methods are being used to search for new ataxia genes and biomarkers in autosomal recessive ataxias and early onset ataxias with onset before the age of 40.
COG-HF (Mechanisms of cognitive impairment in chronic heart insufficiency)
Chronic heart failure (chronically reduced pumping capacity) can lead to impairments in memory or other mental functions. The causes of this are still mainly unclear and will be investigated in this study.
DANCER (Establishment of a Recruitment Pool of Potential Study Participants, of Realtives and a Control Group for DZNE Studies)
One focus of these studies is the identification of early, specific changes, for example in the blood, so that the diagnosis of a neurodegenerative disease such as dementia or Parkinson's can be made at a very early stage. This enables a better understanding of the diseases and supports the development of new forms of therapy.
DANCER-FTD (Recruitment of Realtives and a Control Group for the DESCRIBE-FTD Study)
DANCER-PSP (Recruitment of Realtives and a Control Group for the DESCRIBE-PSP Study)
DESCRIBE (DZNE - Clinical Register Study of neurodegenerative Disorders)
The aim of the DESCRIBE study is to use the examination results obtained in the course of normal patient care together with findings from diagnostics on biomaterials, including genetic analysis, for scientific purposes.
DESCRIBE-FTD (DZNE - Clinical Registry Study on Frontotemporal Dementia (FTD))
DESCRIBE-PSP (DZNE - Clinical Registry Study on Progressive Supranuclear Paresis (PSP))
DIAN (Longitudinal Study on Dominantly Inherited Alzheimer's Disease)
Hereditary Alzheimer's disease, caused by gene mutations, is extremely rare - but those who carry it inevitably develop dementia, usually even before the age of 60. The DIAN network wants to gain insights from this for the very common sporadic Alzheimer's dementia and future therapies.
DZNE Clinical Ataxia Network
Overview of studies belonging to the DZNE Clinical Ataxia Network.
Education for relatives "Living with dementia"
Training series for relatives: Positive effects in care by providing background knowledge and showing possibilities in the daily handling of people with dementia as well as suitable relief and care strategies so that people with dementia can be cared for longer in the home.
ENABLE (Patient- and care-related benefits of amyloid PET imaging)
The aim of the ENABLE trial is to test whether amyloid PET screening has the potential to improve the care of dementia patients in the German health care system and thus contribute to the preservation or slowed loss of everyday functions.
EnergI (Endurance training in old age)
EnergI is an intervention study investigating the acute and long-term impact of 4 months of moderate endurance training on cognitive performance and brain function in aged individuals with metabolic risk factors and protein deposition.
ESMI (European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative)
The aim of this study is to assemble a trial-ready cohort of sufficient size consisting of patients with spinocerebellar ataxia type 3 (SCA 3) and first-degree relatives, so-called at-risk individuals, for future drug trials.
Eye and neurodegeneration
Eye and neurodegeneration: Changes in nerve fibers and vessels in the eye in neurodegenerative diseases.
HSP-Net (Networking Project on Hereditary Spastic Paraplegia)
Spastic spinal paralysis (HSP) is a rare, often hereditary, slowly progressive disease characterized by a spastic gait disorder. The HSP project involves the establishment and conduct of a multicenter study of the natural longitudinal course of hereditary spastic spinal paralysis.
Locus Coeruleus-to-Pons Intensity Ratio as Clinical Biomarker for AD
This study investigates whether patients with different stages of dementia can be accurately diagnosed using LC-to-pons intensity ratio on neuromelanin-sensitive MRI images.
New Biomarkers of Dementia - MRI, fNIRS, DC-Potential, Herzfrequenz
The study addresses the combination of physiological parameters that can potentially detect declining brain function in dementia at an early stage.
NIO752 (Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy)
Adult patients suffering from progressive supranuclear gaze palsy (PSP) are eligible for enrollment in this study. Gaze palsy is a form of atypical Parkinson's syndrome.
ORCHESTRA (Clinical research study to evaluate the use of an investigational medication called UCB0599 in men and women with early-stage Parkinson’s disease)
This study investigates the safety, tolerability, and pharmacokinetics of orally administered UCB0599 in study participants with early-stage Parkinson's disease.
Prospect-AD (Population-based screening over speech for clinical trials in Alzheimer’s Disease)
Subjective memory impairment (SCD) or mild cognitive impairment (MCI) may be associated with an increased risk of dementia later in life. Early preventive measures can potentially reduce the risk of dementia. This requires early detection of early signs of cognitive impairment.
SCA Registry (Registry for Spinocerebellar Ataxies (SCA))
The goals of the SCA Registry are to characterize the natural history of the disease, identify prognostic factors, and develop novel imaging and biochemical biomarkers. By including at-risk individuals, we place a special focus on studying the preclinical disease phase.
SPORTAX-NHS (Observational Study on Adult Onset Sporadic Ataxias)
The SPORTAX study aims to precisely characterize the two forms of the disease and to compare the courses of the disease. In addition, factors are to be identified that allow a more precise assignment of the disease at an early stage and that can influence the development of the disease.
Vorinostat_AD (A dose-finding study to address safety (and efficacy) of Vorinostat in Alzheimer‘s Disease)
The objective of this clinical trial is to determine a tolerable and tolerable dose of the drug vorinostat in elderly patients with mild Alzheimer's disease.

Welcome to our website, here you can inform yourself basically cookie-free.

We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.

Your browser allows the setting of cookies: